Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Two Stage Finding Run-in Study of SAR3419, An Anti-CD19 Antibody-Maytansine Conjugate, Administered as a Single Agent by Intravenous Infusion in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

NCT01440179 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT01440179
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01440179 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Two Stage Finding Run-in Study of SAR3419, An Anti-CD19 Antibody-Maytansine Conjugate, Administered as a Single Agent by Intravenous Infusion in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
Lead sponsor
Sanofi
Phase
Phase 2
Overall status
Terminated
Start date
October 31, 2011
Completion date
May 31, 2014
Enrollment
100 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphocytic leukaemia